Device Helps Doctors Select Lungs for Transplant
MONDAY, April 29, 2019 -- The Xvivo Perfusion System has been approved by the U.S. Food and Drug Administration to help doctors determine whether lungs are suitable for transplant, the agency said in a news release.
The device can temporarily ventilate, oxygenate and pump preservation solution through the lungs, allowing a transplant team to conduct a more thorough assessment of lung function.
The device was given limited approval in 2014, curtailing its use to a maximum of 8,000 patients per year, the agency said. The new approval removes that and other restrictions.
Lung transplant remains the only approved treatment for advanced lung disease, and many people die while waiting for donor lungs to become available. On average, 15 percent of donor lungs are suitable for transplant, the FDA said. About 2,530 lung transplants were performed last year, U.S. government statistics show.
The device's most common adverse reactions included bronchial complications, respiratory failure and infections.
The product is produced by the Swedish company Xvivo Perfusion Inc.
© 2020 HealthDay. All rights reserved.
Posted: April 2019
Read this next
By Stefani Kopenec American Heart Association News THURSDAY, Oct. 22, 2020 (American Heart Association News) -- Wendy Wees suffered a miscarriage during her first pregnancy with...
MONDAY, Sept. 21, 2020 -- As the smoke left by wildfires in California and Oregon continues to linger, people exposed to it need to take steps to protect themselves, an expert...
THURSDAY, Sept. 17, 2020 -- People with asthma and other respiratory illnesses need to be aware of the threat that wildfire smoke poses to their breathing and take steps to...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.